Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.06
BSX's Cash to Debt is ranked lower than
94% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 2.75 vs. BSX: 0.06 )
Ranked among companies with meaningful Cash to Debt only.
BSX' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.14 Max: 0.69
Current: 0.06
0.03
0.69
Equity to Asset 0.35
BSX's Equity to Asset is ranked lower than
85% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. BSX: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
BSX' s Equity to Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.50 Max: 0.64
Current: 0.35
0.18
0.64
F-Score: 5
Z-Score: 0.84
M-Score: -2.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -4.37
BSX's Operating margin (%) is ranked lower than
61% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. BSX: -4.37 )
Ranked among companies with meaningful Operating margin (%) only.
BSX' s Operating margin (%) Range Over the Past 10 Years
Min: -53.36  Med: -6.24 Max: 15.41
Current: -4.37
-53.36
15.41
Net-margin (%) -3.20
BSX's Net-margin (%) is ranked lower than
60% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. BSX: -3.20 )
Ranked among companies with meaningful Net-margin (%) only.
BSX' s Net-margin (%) Range Over the Past 10 Years
Min: -56.12  Med: -9.22 Max: 10
Current: -3.2
-56.12
10
ROE (%) -3.70
BSX's ROE (%) is ranked lower than
60% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. BSX: -3.70 )
Ranked among companies with meaningful ROE (%) only.
BSX' s ROE (%) Range Over the Past 10 Years
Min: -44.65  Med: -5.66 Max: 15.12
Current: -3.7
-44.65
15.12
ROA (%) -1.37
BSX's ROA (%) is ranked lower than
54% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 0.42 vs. BSX: -1.37 )
Ranked among companies with meaningful ROA (%) only.
BSX' s ROA (%) Range Over the Past 10 Years
Min: -21.16  Med: -2.76 Max: 7.67
Current: -1.37
-21.16
7.67
ROC (Joel Greenblatt) (%) -15.99
BSX's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. BSX: -15.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BSX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -153.31  Med: -18.70 Max: 75.09
Current: -15.99
-153.31
75.09
Revenue Growth (3Y)(%) 3.50
BSX's Revenue Growth (3Y)(%) is ranked higher than
50% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. BSX: 3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BSX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.5  Med: 2.35 Max: 28.7
Current: 3.5
-10.5
28.7
EBITDA Growth (3Y)(%) -32.60
BSX's EBITDA Growth (3Y)(%) is ranked lower than
89% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. BSX: -32.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BSX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -72  Med: 11.40 Max: 283.2
Current: -32.6
-72
283.2
» BSX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

BSX Guru Trades in Q1 2015

Pioneer Investments 2,749,545 sh (New)
Alan Fournier 2,880,000 sh (New)
Caxton Associates 225,000 sh (New)
Ray Dalio 111,084 sh (+24.56%)
Vanguard Health Care Fund 59,624,800 sh (unchged)
Michael Price 1,980,000 sh (unchged)
PRIMECAP Management 46,447,349 sh (-1.09%)
Diamond Hill Capital 20,427,155 sh (-12.51%)
Mario Gabelli 1,317,796 sh (-20.16%)
Jim Simons 3,793,655 sh (-28.87%)
Dodge & Cox 729,460 sh (-38.43%)
Steven Cohen 1,705,600 sh (-63.29%)
Paul Tudor Jones 20,554 sh (-87.35%)
» More
Q2 2015

BSX Guru Trades in Q2 2015

Paul Tudor Jones 650,000 sh (+3062.40%)
Steven Cohen 2,790,400 sh (+63.60%)
Pioneer Investments 3,486,551 sh (+26.80%)
Alan Fournier 3,545,000 sh (+23.09%)
Ray Dalio 118,384 sh (+6.57%)
Michael Price 1,980,000 sh (unchged)
Vanguard Health Care Fund 59,624,800 sh (unchged)
Caxton Associates Sold Out
PRIMECAP Management 46,097,564 sh (-0.75%)
Diamond Hill Capital 20,217,043 sh (-1.03%)
Dodge & Cox 588,260 sh (-19.36%)
Jim Simons 2,847,305 sh (-24.95%)
Mario Gabelli 963,296 sh (-26.90%)
» More
Q3 2015

BSX Guru Trades in Q3 2015

Andreas Halvorsen 1,611,935 sh (New)
Alan Fournier 4,868,734 sh (+37.34%)
Vanguard Health Care Fund 64,108,690 sh (+7.52%)
Pioneer Investments 3,639,037 sh (+4.37%)
Diamond Hill Capital 20,724,859 sh (+2.51%)
Michael Price 1,980,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 43,608,364 sh (-5.40%)
Steven Cohen 2,638,300 sh (-5.45%)
Mario Gabelli 846,846 sh (-12.09%)
Ray Dalio 103,684 sh (-12.42%)
Dodge & Cox 472,960 sh (-19.60%)
» More
Q4 2015

BSX Guru Trades in Q4 2015

Vanguard Health Care Fund 64,108,690 sh (unchged)
Mario Gabelli 821,746 sh (-2.96%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Boston Scientific Inc

Diamond Hill Capital Comments on Boston Scientific Corp - Oct 17, 2014

Shares of Boston Scientific Corp. (BSX) declined as investors focused on potential liabilities stemming from legal disputes. We continue to see improvement in revenue trends and believe they will be key factors in closing the discount to our estimate of intrinsic value over time.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Boston Scientific Corp - Jul 25, 2014

•Medical device manufacturer Boston Scientific Corp. (BSX) reported solid earnings for the first quarter but investors focused on near-term headwinds in the cardiac-rhythm management business. The company also announced a delay in potential approval for its Watchman’s heart device. Given the breadth of the company’s pipeline, potential for margin upside, and attractive valuation, we continue to like the outlook for the shares going forward.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Boston Scientific Corp - Jun 26, 2014

Medical device manufacturer Boston Scientific Corp. (BSX) benefitted from continued revenue acceleration and the launch of a new high margin stent with the potential for sizeable share gains.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Ratios

vs
industry
vs
history
Forward P/E 15.90
BSX's Forward P/E is ranked higher than
69% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 18.42 vs. BSX: 15.90 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.54
BSX's P/B is ranked lower than
68% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. BSX: 3.54 )
Ranked among companies with meaningful P/B only.
BSX' s P/B Range Over the Past 10 Years
Min: 0.59  Med: 1.37 Max: 5.96
Current: 3.54
0.59
5.96
P/S 3.02
BSX's P/S is ranked lower than
64% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. BSX: 3.02 )
Ranked among companies with meaningful P/S only.
BSX' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 2.22 Max: 4.37
Current: 3.02
1.02
4.37
PFCF 47.49
BSX's PFCF is ranked lower than
68% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 33.85 vs. BSX: 47.49 )
Ranked among companies with meaningful PFCF only.
BSX' s PFCF Range Over the Past 10 Years
Min: 7.25  Med: 19.47 Max: 192.5
Current: 47.49
7.25
192.5
POCF 31.96
BSX's POCF is ranked lower than
72% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 21.54 vs. BSX: 31.96 )
Ranked among companies with meaningful POCF only.
BSX' s POCF Range Over the Past 10 Years
Min: 5.67  Med: 14.99 Max: 64.6
Current: 31.96
5.67
64.6
EV-to-EBIT -47.39
BSX's EV-to-EBIT is ranked lower than
99.99% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 21.98 vs. BSX: -47.39 )
Ranked among companies with meaningful EV-to-EBIT only.
BSX' s EV-to-EBIT Range Over the Past 10 Years
Min: -129.9  Med: -3.10 Max: 25838
Current: -47.39
-129.9
25838
EV-to-EBITDA -238.17
BSX's EV-to-EBITDA is ranked lower than
99.99% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 16.86 vs. BSX: -238.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -680.1  Med: 8.60 Max: 180
Current: -238.17
-680.1
180
Current Ratio 1.55
BSX's Current Ratio is ranked lower than
76% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.82 vs. BSX: 1.55 )
Ranked among companies with meaningful Current Ratio only.
BSX' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.50 Max: 3.46
Current: 1.55
0.52
3.46
Quick Ratio 1.06
BSX's Quick Ratio is ranked lower than
78% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. BSX: 1.06 )
Ranked among companies with meaningful Quick Ratio only.
BSX' s Quick Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.15 Max: 2.2
Current: 1.06
0.33
2.2
Days Inventory 167.17
BSX's Days Inventory is ranked lower than
61% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 136.13 vs. BSX: 167.17 )
Ranked among companies with meaningful Days Inventory only.
BSX' s Days Inventory Range Over the Past 10 Years
Min: 95.18  Med: 124.41 Max: 152.19
Current: 167.17
95.18
152.19
Days Sales Outstanding 62.24
BSX's Days Sales Outstanding is ranked higher than
56% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 69.24 vs. BSX: 62.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.14  Med: 61.51 Max: 66.79
Current: 62.24
54.14
66.79
Days Payable 35.12
BSX's Days Payable is ranked lower than
74% of the 255 Companies
in the Global Medical Devices industry.

( Industry Median: 60.71 vs. BSX: 35.12 )
Ranked among companies with meaningful Days Payable only.
BSX' s Days Payable Range Over the Past 10 Years
Min: 21.66  Med: 32.69 Max: 340.03
Current: 35.12
21.66
340.03

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.16
BSX's Price/Projected FCF is ranked lower than
58% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 1.94 vs. BSX: 2.16 )
Ranked among companies with meaningful Price/Projected FCF only.
BSX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.5  Med: 1.40 Max: 5.76
Current: 2.16
0.5
5.76
Price/Median PS Value 1.36
BSX's Price/Median PS Value is ranked lower than
72% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. BSX: 1.36 )
Ranked among companies with meaningful Price/Median PS Value only.
BSX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.48  Med: 1.39 Max: 4.3
Current: 1.36
0.48
4.3
Price/Graham Number 2.91
BSX's Price/Graham Number is ranked lower than
99.99% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. BSX: 2.91 )
Ranked among companies with meaningful Price/Graham Number only.
BSX' s Price/Graham Number Range Over the Past 10 Years
Min: 0.36  Med: 5.07 Max: 62.75
Current: 2.91
0.36
62.75
Earnings Yield (Greenblatt) (%) -2.10
BSX's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. BSX: -2.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BSX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 4.10 Max: 9.1
Current: -2.1
0.5
9.1
Forward Rate of Return (Yacktman) (%) 44.14
BSX's Forward Rate of Return (Yacktman) (%) is ranked higher than
98% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 5.80 vs. BSX: 44.14 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BSX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.1  Med: 7.30 Max: 43.2
Current: 44.14
3.1
43.2

More Statistics

Revenue(Mil) $7386
EPS $ -0.30
Beta1.03
Short Percentage of Float2.66%
52-Week Range $14.18 - 19.06
Shares Outstanding(Mil)1345.20

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 7,967 8,441
EPS($) 0.99 1.09
EPS without NRI($) 0.99 1.09

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:BSX.Germany,
Boston Scientific Inc is a developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. The Company's products were offered for sale by seven core businesses - Interventional Cardiology, Cardiac Rhythm Management (CRM), Endoscopy, Peripheral Interventions (PI), Urology and Women's Health, Neuromodulation, and Electrophysiology (EP). market a broad portfolio of internally-developed and self-manufactured drug-eluting stents including the Promus Element and Promus Element Plus everolimus-eluting stents, as well as its TAXUS Element and Ion paclitaxel-eluting stents. The Company sell various products designed to treat patients with peripheral disease (disease which appears in blood vessels other than in the heart and in the biliary tree), including a broad line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. Its peripheral angioplasty balloon technology includes its next-generation Mustang PTA balloon, its Coyote balloon catheter, a deliverable and ultra-low profile balloon dilatation catheter designed for a wide range of peripheral angioplasty procedures, and its Charger PTA Balloon Catheter, a 0.035" percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company also sell products designed to treat patients with non-vascular disease (disease that appears outside the blood system). Its non-vascular suite of products includes biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continue to market its extensive line of Interventional Oncology product solutions, including the recently launched Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company develop, manufacture and market a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including: Implantable cardioverter defibrillator (ICD), Implantable pacemaker systems. During 2013, the company marketed its products to over 13,000 hospitals, clinics, outpatient facilities and medical offices in approximately 100 countries. The Company is subject to various environmental laws, directives and regulations both in the U.S. and abroad. Its operations, like those of other medical device companies, involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes.
» More Articles for BSX

Headlines

Articles On GuruFocus.com
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Third Point's Third Quarter Letter Nov 02 2015 
Endo Pharmaceuticals Posts A Solid Q1 Earnings Report May 12 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
Diamond Hill Select Fund Q4 2014 Commentary Mar 17 2015 
Boston Scientific Finally Wins Positive Nod For Watchman Heart Device In U.S. Leaving Investors Impr Mar 17 2015 
Endo International Shares Upbeat After Positive Q4 Earnings Report Mar 03 2015 
Enphase Energy (ENPH) Record-Breaking Growth, Boston Scientific (BSX) and Johnson & Johnson (JNJ) En Feb 18 2015 
A Robust Q4 Earnings Report From Boston Scientific Feb 10 2015 
Edwards Lifesciences a Gold Standard in the Market Dec 16 2014 

More From Other Websites
Boston Scientific Corp. Earnings Analysis: 2015 By the Numbers Feb 05 2016
Earnings Recap For February 4 Feb 04 2016
Edited Transcript of BSX earnings conference call or presentation 4-Feb-16 1:00pm GMT Feb 04 2016
GoPro (GPRO), Ralph Lauren (RL) and 3 Other Companies Join the Growing List of Stocks Battered by... Feb 04 2016
Heart device maker Boston Scientific's sales miss estimates Feb 04 2016
Boston Scientific Tops Q4 Earnings; CRM Remains a Drag Feb 04 2016
Abiomed, Boston Scientific Move Opposite Ways On Quarterly Reports Feb 04 2016
Boston Scientific (BSX) Stock Declining After Earnings Results Feb 04 2016
Boston Scientific Corp Earnings Call scheduled for 8:00 am ET today Feb 04 2016
Boston Scientific (BSX) Tops Q4 Earnings, Lags Revenue Estimates Feb 04 2016
[$$] Boston Scientific Narrows Loss as Sales Rise Feb 04 2016
Boston Scientific matches profit expectations, but sales fall shy Feb 04 2016
Q4 2015 Boston Scientific Corp Earnings Release - Before Market Open Feb 04 2016
Boston Scientific reports 4Q loss Feb 04 2016
Boston Scientific reports 4Q loss Feb 04 2016
Boston Scientific reports 4.8 pct rise in quarterly revenue Feb 04 2016
6:39 am Boston Scientific beats by $0.01, reports revs in-line; guides Q1 in-line and FY16 EPS... Feb 04 2016
BOSTON SCIENTIFIC CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 04 2016
Boston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2015 Feb 04 2016
Boston Scientific (BSX) Stock Falling Ahead of Q4 Earnings Release Feb 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK